Rolling Out4h
Advanced gene therapy lights hope for vision loss patients
Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...
Gene therapy experiment gives children 'life-changing' sight boost
An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...
What a $2 million per dose gene therapy reveals about drug pricing
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Blind Children See for the First Time Thanks to a Revolutionary Gene Therapy
A groundbreaking gene therapy has restored sight in four young children born with severe blindness due to a rare genetic ...
6-Year-Old Boy Who Was Born Blind Gets Vision Partially Restored After ‘Life-Changing’ Gene Therapy
A Connecticut boy is among four children all born with severe childhood blindness who gained “life-changing improvements” to ...
stocknews2d
3 Gene Therapy Stocks With Game-Changing Potential
Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...
FierceBiotech2d
MeiraGTx gene therapy allows 11 blind children to see as biotech eyes accelerated approval
Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...
IFLScience on MSN2d
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical Trials
A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.